Home » Stocks » CDXI

Cardax Inc. (CDXI)

Stock Price: $1.26 USD 0.00 (0.00%)
Updated Aug 2, 2021 9:30 AM EDT - Market closed
Market Cap 1.01M
Revenue (ttm) 500,707
Net Income (ttm) -5.43M
Shares Out 802,516
EPS (ttm) -7.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 2
Last Price $1.26
Previous Close $1.26
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.26
Day's Range 1.26 - 1.26
Day's Volume 0
52-Week Range 1.15 - 5.00

News

There are no news available yet.

About CDXI

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a targ... [Read more...]

Industry
Biotechnology
Stock Exchange
OTCMKTS
Ticker Symbol
CDXI
Full Company Profile

Financial Performance

In 2020, Cardax's revenue was $538,946, a decrease of -24.19% compared to the previous year's $710,949. Losses were -$5.06 million, -0.74% less than in 2019.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Cardax is 1.00, which is a decrease of -20.63% from the latest price.

Price Target
$1.00
(-20.63% downside)